U.S. markets closed

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)

NSE - NSE Real Time Price. Currency in INR
Add to watchlist
528.85-0.10 (-0.02%)
At close: 3:29PM IST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close528.95
Open537.90
Bid0.00 x 0
Ask0.00 x 0
Day's Range527.05 - 538.00
52 Week Range312.00 - 541.00
Volume10,927,314
Avg. Volume10,757,350
Market Cap1.269T
Beta (5Y Monthly)0.28
PE Ratio (TTM)175.76
EPS (TTM)3.01
Earnings DateN/A
Forward Dividend & Yield6.75 (1.28%)
Ex-Dividend DateAug 19, 2020
1y Target Est567.59
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Sun Pharma latest to sell COVID-19 drug favipiravir in India
      Reuters

      Sun Pharma latest to sell COVID-19 drug favipiravir in India

      India's Sun Pharmaceutical Industries Ltd said on Tuesday it would soon begin selling its version of favipiravir, becoming the latest generic drugmaker to supply the antiviral to treat COVID-19 in the world's third worst-hit nation. Favipiravir, along with another antiviral, remdesivir, has emerged as one of the most sought-after drugs at hospitals fighting COVID-19 in India, which saw a surge of 50,000-plus infections for the sixth straight day on Tuesday. Sun's version of favipiravir, to be called FluGuard, will cost 35 rupees (47 cents) per 200 mg tablet, making it the cheapest version available.

    • Sun Pharma testing plant-based drug as potential COVID-19 treatment
      Reuters

      Sun Pharma testing plant-based drug as potential COVID-19 treatment

      Indian drugmaker Sun Pharmaceutical Industries Ltd said on Friday it was testing a plant-derived drug, AQCH, for the potential treatment of COVID-19 as part of a mid-stage trial, with results expected by October. AQCH is derived from tropical, climbing shrub cocculus hirsutus, which is used in Asia for its apparent medicinal properties. The company said the trial will be conducted across 12 centers in India in 210 patients and a human safety study of the drug has been completed.

    • Sun Pharma to test pancreatitis drug in COVID-19 patients in India
      Reuters

      Sun Pharma to test pancreatitis drug in COVID-19 patients in India

      Drugmaker Sun Pharmaceutical Industries Ltd said on Friday it has received Indian regulatory approval to start clinical trials of a pancreatitis drug in COVID-19 patients. The company joins other Indian drugmakers Glenmark Pharmaceuticals Ltd and Strides Pharma Science Ltd that are conducting trials in India for potential drugs for COVID-19, which currently has no approved treatment or vaccine. Sun Pharma said http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200529:nBSE5stp4F the pancreatitis drug, nafamostat mesilate, has been "identified as a potential candidate for COVID-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany".